Rhythm Pharmaceuticals
151 articles about Rhythm Pharmaceuticals
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - April 16, 2024
4/16/2024
Rhythm Pharmaceuticals, Inc. announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 14,740 shares of its common stock.
-
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
4/1/2024
Rhythm Pharmaceuticals, Inc. announced that it has signed an investment agreement with current shareholders, led by Perceptive Advisors LLC and its Discovery Fund and a life-sciences focused institutional investor, for the sale of its series A convertible preferred stock for gross proceeds of $150 million to the Company.
-
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
3/25/2024
Rhythm Pharmaceuticals, Inc. today announced that the first patients have been dosed in the Company’s Phase 1 clinical trial of RM-718, an investigational, weekly melanocortin-4 receptor (MC4R)-specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - March 11, 2024
3/11/2024
Rhythm Pharmaceuticals, Inc. announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 9,180 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,600 shares of its common stock.
-
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences - March 06, 2024
3/6/2024
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, announced that the Company will participate in two upcoming investor conferences.
-
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
2/22/2024
Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
-
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
2/22/2024
Rhythm Pharmaceuticals, Inc. announced plans to add a cohort of patients with hypothalamic obesity in Japan to its ongoing global Phase 3 clinical trial of setmelanotide, with dosing expected to begin in the third quarter of 2024.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - February 08, 2024
2/8/2024
Rhythm Pharmaceuticals, Inc. announced that on February 2, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 20,295 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 13,530 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 6,765 shares of its common stock.
-
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
2/7/2024
Rhythm Pharmaceuticals, Inc. today announced that the Italian Medicine Agency (AIFA) approved reimbursement ( Gazzetta Ufficiale ) for IMCIVREE ® (setmelanotide) for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome (BBS).
-
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
1/31/2024
Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - Jan 12, 2024
1/12/2024
Rhythm Pharmaceuticals, Inc. announced that on January 9, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,020 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 8,680 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,340 shares of its common stock.
-
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
1/4/2024
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today provided a business update and announced it has completed screening for enrollment in the pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity.
-
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
1/4/2024
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced it has entered into a global licensing agreement with LG Chem, Ltd. ("LG Chem"), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - December 15, 2023
12/15/2023
Rhythm Pharmaceuticals, Inc. announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 10,500 shares of its common stock to one new employee, consisting of inducement stock options to purchase an aggregate of 7,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 3,500 shares of its common stock.
-
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
12/13/2023
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, is pleased to be a sponsor of the second annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) that is being held in Paris, France from December 13-15.
-
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
12/6/2023
Rhythm Pharmaceuticals, Inc. hosted an R&D event for investors and analysts, “Rhythm Update on MC4R Pathway Programs.”
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - November 13, 2023
11/13/2023
Rhythm Pharmaceuticals, Inc. announced that on November 8, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 6,765 shares of its common stock to two new employees, consisting of inducement stock options to purchase an aggregate of 4,510 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 2,255 shares of its common stock.
-
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
11/7/2023
Rhythm Pharmaceuticals, Inc. reported financial results and provided a business update for the third quarter ended September 30, 2023.
-
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
11/2/2023
Rhythm Pharmaceuticals, Inc. today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that IMCIVREE® (setmelanotide) be reimbursed by CADTH-participating public drug plans, with conditions, for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS).
-
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
10/25/2023
Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report its third quarter 2023 financial results and provide a corporate update.